Cigna earnings beat by $0.04, revenue topped estimates
On Monday, RBC Capital Markets adjusted its price target on HCA Healthcare Inc (NYSE:HCA) shares, reducing it to $376 from the previous $384, while retaining an Outperform rating. The healthcare giant, with a market capitalization of $80.7 billion and an impressive "GREAT" financial health score according to InvestingPro, faces ongoing policy uncertainties affecting the healthcare sector, including Medicaid coverage, exchange subsidies, state-directed payments, and tariffs.
The firm’s analyst noted that despite policy challenges, HCA Healthcare’s management has effectively executed on factors within their control. The company’s performance in the first quarter, particularly regarding patient acuity trends, is seen as a positive aspect that might not have been fully recognized due to the optics around surgical volume, which was affected in part by the number of days in the period. This execution is reflected in the company’s solid 7.3% revenue growth and healthy 40.9% gross profit margin over the last twelve months.
The analyst pointed out that while the Direct Patient Payment (DPP) issue continues to be a concern for investors, HCA Healthcare has kept a consistent guidance stance. Additionally, the company benefited from a state reconciliation payment, which provided a boost in the first quarter of 2025.
HCA Healthcare’s management has demonstrated resilience in navigating the current healthcare landscape, balancing investor concerns with operational consistency. The firm’s maintained Outperform rating indicates confidence in the company’s ongoing performance despite the slight revision of the price target.
In other recent news, HCA Healthcare reported impressive financial results for the first quarter of 2025. The company surpassed earnings expectations with an earnings per share (EPS) of $6.45, beating the analyst forecast of $5.78. Revenue also exceeded predictions, reaching $18.32 billion compared to the anticipated $18.26 billion. Despite these strong financial results, HCA’s stock experienced a decline, which may be attributed to broader market concerns. Additionally, the company has been actively expanding its operations, having completed acquisitions of Catholic Medical (TASE:BLWV) Center in New Hampshire and Lehigh Medical Center in Florida. HCA Healthcare also sold the Regional Medical Center of San Jose as part of its portfolio optimization strategy. Furthermore, the company is continuing its focus on digital transformation and AI investments to enhance operational efficiency. HCA’s full-year guidance for 2025 remains unchanged, with expectations for admissions growth and significant capital expenditures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.